Trial · NCT03128463
Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases
NCT03128463, Unknown, Xun Xu
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases. Trials, record NCT03128463. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03128463
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases
- NCT number
- NCT03128463
- Status
- Unknown
- Enrollment
- 5,000 participants, estimated
- Lead sponsor
- Xun Xu
- Conditions
- Age-Related Macular Degeneration, Polypoidal Choroidal Vasculopathy, Pathological Myopia, Conbercept, Pharmacogenomic
- Interventions
- Intravitreal injection of conbercept
- First posted
- 2017-04-25
- Last updated
- 2017-04-25
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | visual improvement after intravitreal injection of conbercept | Feb. 2017-Dec.2018 | The efficacy was graded as significantly effective (visual improvement ≥15 letters in EDTRS )，effective (visual improvement ≥5 letters and \<15 letters in EDTRS），invalid（visual improvement \<5 letters and visual reduction\<5 letters in EDTRS， deterioration （visual reduction≥5 letters in EDTRS. The number and ratio of the above-mentioned grade are to be analyzed. |
| Secondary | The off-label use of conbercept in real world. | Feb. 2017-Dec.2018 | Calculate the number of cases and percentage of off-label use（%）in real world. |
| Secondary | The application of off-label use on targeted diseases | Feb. 2017-Dec.2018 | Record the name of diseases when off-label use is applied. |
| Secondary | The number and percentage（%）of each target diseases in off-label use. | Feb. 2017-Dec.2018 | Calculate the the number and percentage（%）of each target diseases in off-label use respectively. |
| Secondary | The improvement of retinal edema after using conbercept | Feb. 2017-Dec.2018 | The improvement of retinal edema after using conbercept and compare the difference between central foveal retinal thickness (CRT in μm) and the baseline after 1 month, 3 months, 6 months, and 12 months. |
| Secondary | The different therapeutic regimens | Feb. 2017-Dec.2018 | The different therapeutic regimens when conbercept is applied on different diseases in real world, including number of treatments, frequency of injection（times per year), interval time(months). |
| Secondary | Dropout rate of the study. | Feb. 2017-Dec.2018 | Calculate the dropout rate（%) of each follow-up time and during the whole follow-up. |
| Secondary | Predict patients' response to conbercept on treating macular neovascular diseases by analyzing macular leakage area | Feb. 2017-Dec.2018 | After 3 months treatment, compare the macular leakage area (mm2) to baseline in Fluorescein Fundus Angiography (FFA) on patients who response to conbercept treatment and patients with no response, to further analyze the potential relationship with the response / non-response. |
| Secondary | Predict patients' response to conbercept on treating macular neovascular diseases by analyzing CNV area | Feb. 2017-Dec.2018 | After 3 months treatment, compare the CNV area (mm2) to baseline in FFA on patients who response to conbercept treatment and patients with no response, to further analyze the potential relationship with the response / non-response. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03128463
GET https://conductscience.org/api/trials/v1/NCT03128463/registered